These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 9264187)

  • 1. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
    Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
    Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
    Nelson TE; Bedell DM; Jones EW
    Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
    Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
    Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the calcium antagonist, TMB-8 on halothane and on caffeine contractures of malignant hyperthermia susceptible skeletal muscle.
    Williams JH; Holland M; Lee JC
    Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):387-90. PubMed ID: 2385762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle.
    Sudo RT; Nelson TE
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1331-6. PubMed ID: 9316843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscles via activation of the ryanodine receptor Ca2+ channel.
    Tegazzin V; Scutari E; Treves S; Zorzato F
    Anesthesiology; 1996 Jun; 84(6):1380-5. PubMed ID: 8669679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The action of ketamine on muscle contractile behavior. In vitro studies on the musculature of subjects susceptible to malignant hyperthermia].
    Hackl W; Winkler M; Mauritz W; Steinbereithner K
    Anaesthesist; 1989 Dec; 38(12):681-5. PubMed ID: 2619030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
    MacLennan DH; Duff C; Zorzato F; Fujii J; Phillips M; Korneluk RG; Frodis W; Britt BA; Worton RG
    Nature; 1990 Feb; 343(6258):559-61. PubMed ID: 1967823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Muldoon S; Bünger R
    Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro determination of susceptibility to malignant hyperthermia.
    Iaizzo PA; Lehmann-Horn F
    Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.